Question to the Department of Health and Social Care:

To ask His Majesty's Government what steps they are taking to ensure that all medicines approved for treatment of osteoporosis by the National Institute for Health and Care Excellence are available in (1) integrated care systems and (2) local formularies.

The National Institute for Health and Care Excellence (NICE) makes recommendations for the National Health Service on whether new licensed medicines should be routinely funded by the NHS based on an assessment of their costs and benefits.

The NHS in England is legally required to fund medicines recommended by the NICE, usually within three months of final guidance.

The 2025/26 NHS Standard Contract, which applies to all contracts between NHS commissioners and providers, stipulates that, where any service involves or may involve the prescribing of medicines, the provider must ensure that its formulary reflects all relevant positive NICE technology appraisals.

The NICE has also published guidance on developing and updating local formularies, which is intended to support commissioners and healthcare providers in developing formularies that reflect local needs, reduce variation in prescribing, and allow for the rapid adoption of new medicines and treatments. Further information is available on the NICE website, in an online only format.